Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 658,100 shares, an increase of 46.2% from the December 31st total of 450,000 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average trading volume of 276,000 shares, the days-to-cover ratio is presently 2.4 days.

Institutional Trading of Vistagen Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Vistagen Therapeutics during the 4th quarter valued at approximately $25,000. Jane Street Group LLC acquired a new stake in shares of Vistagen Therapeutics during the third quarter worth $59,000. Virtu Financial LLC raised its holdings in shares of Vistagen Therapeutics by 30.5% during the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock worth $61,000 after purchasing an additional 4,722 shares during the period. HighTower Advisors LLC acquired a new position in shares of Vistagen Therapeutics in the 3rd quarter valued at about $64,000. Finally, Valence8 US LP bought a new stake in shares of Vistagen Therapeutics during the 3rd quarter valued at about $103,000. 78.39% of the stock is owned by institutional investors.

Vistagen Therapeutics Trading Down 1.7 %

NASDAQ:VTGN traded down $0.05 during trading hours on Friday, hitting $2.89. The stock had a trading volume of 218,479 shares, compared to its average volume of 199,775. The business has a 50 day simple moving average of $2.78 and a two-hundred day simple moving average of $3.06. Vistagen Therapeutics has a 1-year low of $2.22 and a 1-year high of $5.74. The company has a market cap of $80.46 million, a PE ratio of -2.33 and a beta of 0.78.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). Vistagen Therapeutics had a negative net margin of 4,521.71% and a negative return on equity of 36.35%. The firm had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.34 million. During the same period in the previous year, the company earned ($0.66) earnings per share. Research analysts expect that Vistagen Therapeutics will post -1.85 EPS for the current fiscal year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.